Revive Therapeutics Ltd. announced that Tessio Rebello, Ph.D., will join the Company as a clinical advisor for the Company. Dr. Rebello previously held the position of Vice President of Clinical Development at VIRxSYS Corporation where he led the successful launch of anti-sense, gene therapy (VRX496), Phase 2 clinical trial for the treatment of HIV-infected patients who fail to respond to conventional drug therapies and two other Phase 2 clinical trials involving the same drug.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.02 CAD | 0.00% | 0.00% | -33.33% |
1st Jan change | Capi. | |
---|---|---|
-33.33% | 6.11M | |
+15.53% | 121B | |
+18.49% | 112B | |
+4.43% | 22.57B | |
-18.02% | 20.82B | |
-14.36% | 16.3B | |
-16.61% | 16.19B | |
-43.53% | 16.17B | |
+1.49% | 13.17B | |
+25.19% | 11.11B |
- Stock Market
- Equities
- RVV Stock
- News Revive Therapeutics Ltd.
- Revive Therapeutics Appoints Tessio Rebello as Clinical Advisor